Showing results (51-60 of 60) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Scientific Reports|May 16, 2024
Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanomaLindsay V M Leek, Jessica C L Notohardjo, Karlijn de Joode, et al.Journal of Thrombosis and Haemostasis : JTH|August 19, 2021
Evaluation of the Khorana, PROTECHT, and 5-SNP scores for prediction of venous thromboembolism in patients with cancerNoori A M Guman, Roos J van Geffen, Frits I Mulder, et al.Circulation. Genomic and Precision Medicine|April 10, 2026
Tumor Whole-Genome Sequencing for Prediction of Venous Thromboembolism in Patients With Metastasized Solid CancerFrits I Mulder, Noori A M Guman, Job van Riet, et al.European Journal of Cancer (Oxford, England : 1990)|May 28, 2026
AI-based histopathology analysis predicts checkpoint inhibitor response in advanced melanoma and identifies patterns associated with responseMark Schuiveling, Isabella A J van Duin, Laurens S Ter Maat, et al.BMC Cancer|March 4, 2023
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumoursBirgit S Geurts, Thomas W Battaglia, J Maxime van Berge Henegouwen, et al.Journal of the National Cancer Institute|February 21, 2025
Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort studyMark Schuiveling, Laurens S Ter Maat, Isabella A J Van Duin, et al.European Journal of Cancer (Oxford, England : 1990)|June 21, 2024
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanomaRik J Verheijden, Femke H Burgers, Josephine C Janssen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2024
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery ProtocolLaurien J Zeverijn, Birgit S Geurts, Thomas W Battaglia, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided TreatmentLouisa R Hoes, Jade M van Berge Henegouwen, Hanneke van der Wijngaart, et al.Cancer Cell|May 30, 2025
The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targetsJaco C Knol, Mengge Lyu, Franziska Böttger, et al.Pageof 6